Frontotemporal Dementias

Dr. Bernardino Ghetti is a Distinguished Professor at Indiana University, and serves as the first President of the International Society for Frontotemporal Dementias. Dr. Bradley Boeve is a professor of neurology and a consultant in the Department of Neurology at the Mayo Clinic in Rochester, MN. Dr. Emannuele Buratti is the Group Leader in the Molecular Pathology Laboratory at the International Center for Genetic Engineering and Biotechnology in Trieste, Italy. Dr. Rosa Rademakers is a Professor of Neurogenetics at the University of Antwerpen in Antwerpen, Belgium.

1. Behavioural variant FTD: recent advances in the diagnosis and understanding of the disorder.- 2. The neuropsychiatry of frontotemporal dementia.- 3. Nosology and Neuropathology of Language in Primary Progressive Aphasia.- 4. Measuring Behavior and Cognition in FTLD.- 5.  Clinical update on C9orf72: FTD, ALS and beyond.- 6. Clinical aspects of familial FTLD associated with MAPT and GRN mutations.- 7. Neuroimaging in Frontotemporal Lobar Degeneration.- 8. The FTD Prevention Initiative - linking together genetic FTD cohort studies.- 9. Fluid Biomarkers of Frontotemporal Lobar Degeneration.- 10. Cross-cultural perspectives on frontotemporal degeneration.- 11. Clinical characteristics and Neuropathology of PSP, CBD and Related 4R-Tauopathies.- 12. Tau protein and frontotemporal dementias.- 13. FTLD-TDP pathological subtypes: clinical and mechanistic significance.- 14.  Lysosomal dysfunction as a pathogenic mechanism in FTD: Evidence from PGRN and TMEM106B genetics and biology.- 15. Future trends in understanding the pathological role of TDP-43 and FUS proteins.- 16. Description of a new data resource for FTD including multiomic data on human post mortem brain (MAPT, GRN, C9orf72), matching mouse models and iPS models.- 17. Mendelian and sporadic FTD: avenues from genetics to disease pathways through in-silico prediction and modeling.- 18. FTLD treatment:  Current Practice and Future Possibilities.